DPA (Docosapentaenoic Acid)
The overlooked third marine omega-3, sitting between EPA and DHA. Blood levels of DPA track with better cardiometabolic markers, but supplementing purified DPA has barely been tested in humans.
Evidence last reviewed: August 2026
What the science says
- Human supplementation data Limited evidence
The main supplementation study gave 8 g/day of pure DPA or EPA to ten women for seven days and looked only at how the fatty acids were incorporated into plasma and red cells. It measured no health outcome, and a 2021 review still described DPA as the neglected omega-3 with minimal human trial evidence.
- Association with triglycerides and CRP Limited evidence
In healthy adults, red blood cell DPA was inversely associated with triglycerides and C-reactive protein, and rose dose-dependently after conventional EPA and DHA supplementation. This is an observational association within a supplementation study, not proof that taking DPA causes the benefit.
- Advantage over EPA and DHA Limited evidence
No trial has compared DPA against EPA or DHA on any clinical endpoint. Since standard fish oil raises DPA levels anyway, a separate DPA product has no demonstrated added value.
Dosage & safety
Scientific references
- A short-term n-3 DPA supplementation study in humans
- Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation
- n - 3 Docosapentaenoic acid: the iceberg n - 3 fatty acid
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Heart & metabolic
- Vitamin B3 (Niacin) Limited evidence
- Vitamin K2 (MK-7) Limited evidence
- Chromium Limited evidence
- Potassium Strong evidence
- Vanadium Limited evidence
- L-Arginine Moderate evidence